26 Results were found on Technologies


Targeting Bone Neoplasms and Other Cancers with Novel Combined Anticancer and Anti-Angiogenic Polymer Therapeutics

Anti-cancer NanoTherapyUtilizing unique nano-technology to develop targeted combination nanomedicines that were shown to be synergistic, effective and safe for treating cancer TechnologyWe have developed a new platform technology for the treatment of cancer and bone metastases using combined targeted nano-sized polymers that deliver chemotherapeutics creating a new class of effective and safer molecules. The novel […] Read More >


Novel Class of Turn-ON Near-Infrared Probes for Diagnosis and Imaging of Inflammation and Cancer

Complete tumor removal during surgery has a great impact on patient survival. To that end, the surgeon should detect the tumor, remove it and validate that there are no residual cancer cells left behind. Residual cells at the incision margin of the tissue removed during surgery are associated with tumor recurrence and poor prognosis for […] Read More >

Leading Researchers:

Biomarkers for Risk Assessment in Colorectal Cancer Patients

Mortalin (also known as GRP75 and mitochondrial stress protein 70) is a ubiquitously expressed mitochondrial chaperone related to the cytosolic heat shock protein 70 (HSP70). It protects cells from senescence and apoptosis and is overexpressed in most cancer cells. We discovered that cell resistance to complement-dependent cytotoxicity depends on mortalin and that mortalin is released […] Read More >

Leading Researchers:

HBB Peptide for the Treatment of Neuroblastoma (NB) Lung Metastases and Microemetastases

A novel cytotoxic peptide against neuroblastoma (NB) lung metastases and micrometastases, has been developed.  The peptide is derived from the beta-2 subunit of mouse hemoglobin (HBB2), a factor present in the lung microenvironment which inhibits the propagation of micrometastatic NB cells, the key cause of deaths in NB residual disease. The peptide inhibits the viability […] Read More >

Leading Researchers:

Novel Integrase Based Cancer Treatment Technology

We have developed a new gene therapy technology for specific cancer cells killing and validated both efficacy and safety superiority of the proposed system over the conventional one in lung cancer mice model. The proposed system offers advantages over already known counterparts and may therefore be developed into a safer and efficient human cancer treatment […] Read More >

Leading Researchers:

Harnessing Inhibitory RNA Based- Nanoparticles for Therapeutic Intervention in Blood Cancers

The current treatment of multiple myeloma (MM) included standard chemotherapy and small molecules such as the proteasome inhibitor and the immunomodulatory drugs.  Although these drugs have improved the response and survival of MM patients, MM is still an incurable disease. Drug resistance and disease refractoriness are the common terminal pathways leading to patients’ mortality. Therefore, […] Read More >

Leading Researchers:

Inhibition of the Pax8 Transcription Factor as a Novel Therapeutic Approach for Ovarian and Endometrial Cancer

OUTLINEThe PAX8 transcription factor is essential for ovarian cancer proliferation, and its silencing in ovarian and endometrial cancer cells leads to apoptosis 1,2. PAX8 expression in other tissues is restricted to non-essential organs, suggesting that it is a good target for therapy with minimal side effects 3,4. We propose a novel anti-ovarian and -endometrial cancer […] Read More >

Leading Researchers:

An Oncolytic Virus That Exploits Immune Defects of Cancer Cells

An oncolytic virus for tumors of different etiology presenting defects in interferon signaling, designed as a potent, specific and safe therapy.  Promising in-vivo murine melanoma model shows potential for development as a mono or an add-on to chemotherapy or check-point inhibitors. UNMET NEEDOn Nov. 2015 the FDA approved the first oncolytic virus based treatment. Oncolytic […] Read More >

Leading Researchers:

A Novel Nanoparticle that Selectively Delivers RNAi Oligonucelotides to Tumors, Preventing Side Effects to Tissues

UNMET NEEDPancreatic cancer numbers among the most aggressive cancers known today. The overwhelming majority of pancreatic cancer patients pass away within just a year of diagnosis. However, a small minority of patients may live several years with the disease. Our findings pinpoint the inverse correlation between a known oncogene (PLK1) and the expression of an […] Read More >

Leading Researchers:

Novel Ionizable Lipids for Delivery of Nucleic Acids (mRNA, DNA, siRNA)

BackgroundChemotherapy treatment is generally accompanied by adverse effects, which can be significantly reduced using site specific, targeted delivery systems, such as antibody-coated LNPs (immuno-LNPs). However due to inter-and intra-tumor heterogeneity targeting with a single targeting moiety is not sufficient in many cases and in others may induce cancer relapse due to the survival of side […] Read More >

Sorry, no results were found.

Sign up for
our events

    Life Science